+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Pharyngitis Drug Pipeline Analysis Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102722
Pharyngitis, commonly referred to as a sore throat, is an inflammation of the pharynx often caused by infections like Group A Streptococcus (GAS), which is responsible for 14%-37% of cases in higher-income countries, particularly affecting individuals aged 5-19 years. This disease poses a significant clinical burden, with a high unmet need for improved therapies. Current treatments, such as antibiotics, face limitations, including concerns about resistance and recurrence risks. The growing focus on targeted and innovative therapies, including vaccines and novel antimicrobials, is anticipated to drive advancements in the pharyngitis drug pipeline, addressing the gaps in treatment and improving patient outcomes in the coming years.

Report Coverage

The Pharyngitis Drug Pipeline Insight Report by the publisher gives comprehensive insights into pharyngitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pharyngitis. The pharyngitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pharyngitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pharyngitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pharyngitis.

Pharyngitis Drug Pipeline Outlook

Pharyngitis (PKU) is an inflammation of the pharynx, typically caused by viral or bacterial infections. Group A Streptococcus (GAS) is a major bacterial cause, with the disease most commonly affecting children aged 5-19. The condition is often triggered by respiratory infections and can lead to significant discomfort and complications if left untreated.

Pharyngitis treatments mainly include antibiotics for bacterial infections and symptomatic relief for viral cases. Antibiotics like penicillin are used to treat GAS infections, while over-the-counter pain relievers and throat lozenges manage symptoms in viral cases. Despite current treatments, there remains a significant need for more effective therapies to combat recurrent or resistant infections.

Pharyngitis Epidemiology

Pharyngitis, commonly known as sore throat, is a globally prevalent condition. Acute pharyngitis is a widespread condition leading to approximately 12 million annual ambulatory care visits in the United States, accounting for 1-2% of all ambulatory care visits. Children and adolescents are most affected, with 50% of cases occurring before the age of 18. Adults experience an average of 13.5-14.4 episodes per 100 patient-years, while children face up to 82.5 episodes. Moderate-to-severe pain impacts 70% of patients.

Pharyngitis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pharyngitis drug candidates based on several segmentations, including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Biologics
  • Peptides
  • Gene Therapy
  • Immunomodulators
  • Combination Therapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Pharyngitis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total pharyngitis clinical trials.

Pharyngitis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pharyngitis pipeline analysis include small molecules, biologics, peptides, gene therapy, immunomodulators, and combination therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pharyngitis.

Pharyngitis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The pharyngitis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pharyngitis clinical trials:
  • Dexa Medica
  • Genentech Inc.
  • Bausch Health Companies Inc.
  • Adamas Pharmaceuticals Inc.
  • Boehringer Ingelheim
  • Pfizer
  • Bayer
  • Sandoz Pharmaceuticals GmbH

Pharyngitis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pharyngitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pharyngitis drug candidates.

Drug: Phenoxymethylpenicillin

The Phase 4 study is evaluating the effectiveness of phenoxymethylpenicillin versus no antibiotic treatment for Group A Streptococcus-negative sore throat in patients aged 15 and older. The randomized trial, with an estimated enrollment of 260 participants, aims to assess symptom duration and intensity. Completion is anticipated by June 2026.

Drug: Qingyan Lihou Decoction

The Chinese University of Hong Kong is sponsoring a Phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Qingyan Lihou Decoction for treating chronic pharyngolaryngitis, a persistent form of pharyngitis. With 74 participants, the study aims to assess symptom relief over an 8-week treatment period, followed by an 8-week post-treatment evaluation.

Drug: Benzydamine Hydrochloride

This study aims to evaluate the effectiveness of Benzydamine Hydrochloride spray (Difflam) in reducing postoperative sore throat (POST) after the use of a laryngeal mask airway use. This early phase 1 study, involving 106 participants, is expected to be completed by December 2026. The objective is to assess POST incidence, pain severity, and spray safety in perioperative care.

Reasons To Buy This Report

The Pharyngitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pharyngitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pharyngitis collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Pharyngitis - Pipeline Insight Report

  • Which companies/institutions are leading the pharyngitis drug development?
  • What is the efficacy and safety profile of pharyngitis pipeline drugs?
  • Which company is leading the pharyngitis pipeline development activities?
  • What is the current pharyngitis commercial assessment?
  • What are the opportunities and challenges present in the pharyngitis drug pipeline landscape?
  • What is the efficacy and safety profile of pharyngitis pipeline drugs?
  • Which company is conducting major trials for pharyngitis drugs?
  • Which companies/institutions are involved in pharyngitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in pharyngitis?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Pharyngitis
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Pharyngitis
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Pharyngitis: Epidemiology Snapshot
5.1 Pharyngitis Incidence by Key Markets
5.2 Pharyngitis - Patients Seeking Treatment in Key Markets
6 Pharyngitis: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Pharyngitis: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Pharyngitis, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Pharyngitis Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Pharyngitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Phenoxymethylpenicillin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Other Drugs
11 Pharyngitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Qingyan Lihou Decoction
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Pharyngitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Pharyngitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug: Benzydamine Hydrochloride
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Pharyngitis, Key Drug Pipeline Companies
14.1 Dexa Medica
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Genentech Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Bausch Health Companies Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Adamas Pharmaceutical Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Boehringer Ingelheim
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Pfizer
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Bayer
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Sandoz Pharmaceuticals GmbH
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products